Cargando…

Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma

SIMPLE SUMMARY: Despite the advances in treatment of patients diagnosed with advanced melanoma, long-term benefits remain limited due to primary and acquired resistance. Reliable biomarkers may support treatment decisions and should optimize treatment efficacy. By using a homogeneous population of m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wendlinger, Simone, Wohlfarth, Jonas, Kreft, Sophia, Siedel, Claudia, Kilian, Teresa, Dischinger, Ulrich, Heppt, Markus V., Wistuba-Hamprecht, Kilian, Meier, Friedegund, Goebeler, Matthias, Schadendorf, Dirk, Gesierich, Anja, Kosnopfel, Corinna, Schilling, Bastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104271/ https://www.ncbi.nlm.nih.gov/pubmed/35565423 http://dx.doi.org/10.3390/cancers14092294

Ejemplares similares

Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion
por: Kosnopfel, Corinna, et al.
Publicado: (2023)

PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma
por: Glutsch, Valerie, et al.
Publicado: (2022)

Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer
por: Wistuba-Hamprecht, Kilian, et al.
Publicado: (2020)

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
por: Bochem, Jonas, et al.
Publicado: (2019)

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
por: Gaißler, Andrea, et al.
Publicado: (2023)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
por: Glutsch, Valerie, et al.
Publicado: (2019)

Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives
por: Buder, Kristina, et al.
Publicado: (2013)

Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
por: Schummer, Patrick, et al.
Publicado: (2020)

Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study
por: Tomsitz, Dirk, et al.
Publicado: (2023)

Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade
por: Gaißler, Andrea, et al.
Publicado: (2022)

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma
por: Simon, Bianca, et al.
Publicado: (2018)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

Immunomonitoring of Human Breast Milk Cells During HCMV-Reactivation
por: Lazar, Katrin, et al.
Publicado: (2021)

Age-associated alterations in γδ T-cells are present predominantly in individuals infected with Cytomegalovirus
por: Wistuba-Hamprecht, Kilian, et al.
Publicado: (2013)

Peripheral blood T-cell signatures from high-resolution immune phenotyping of γδ and αβ T-cells in younger and older subjects in the Berlin Aging Study II
por: Wistuba-Hamprecht, Kilian, et al.
Publicado: (2015)

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
por: Bochem, Jonas, et al.
Publicado: (2021)

Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
por: Glutsch, Valerie, et al.
Publicado: (2022)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
por: Koch, Elias A. T., et al.
Publicado: (2022)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
por: Koch, Elias A. T., et al.
Publicado: (2021)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
por: Heppt, Markus V., et al.
Publicado: (2019)

Genetic Influence on the Peripheral Differentiation Signature of Vδ2+ γδ and CD4+ αβ T Cells in Adults
por: Beucke, Nicola, et al.
Publicado: (2021)

S(3)-CIMA: Supervised spatial single-cell image analysis for identifying disease-associated cell-type compositions in tissue
por: Babaei, Sepideh, et al.
Publicado: (2023)

One Website to Gather them All: Usability Testing of the New German SKin Cancer INFOrmation (SKINFO) Website—A Mixed-methods Approach
por: Steeb, Theresa, et al.
Publicado: (2022)

Single-cell trajectories of melanoma cell resistance to targeted treatment
por: Schmidt, Maria, et al.
Publicado: (2022)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
por: Kosnopfel, Corinna, et al.
Publicado: (2017)

Assessment of the Quality, Understandability, and Reliability of YouTube Videos as a Source of Information on Basal Cell Carcinoma: Web-Based Analysis
por: Steeb, Theresa, et al.
Publicado: (2022)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
por: Isberner, Nora, et al.
Publicado: (2022)

Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition
por: Makino, Elena, et al.
Publicado: (2020)

Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study
por: Scherzad, Agmal, et al.
Publicado: (2023)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
por: Heppt, Markus V., et al.
Publicado: (2017)

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
por: Turiello, Roberta, et al.
Publicado: (2020)

Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
por: Gellrich, Frank Friedrich, et al.
Publicado: (2020)

Lack of SF3B1 R625 mutations in cutaneous melanoma
por: Schilling, Bastian, et al.
Publicado: (2013)

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
por: Makino, Elena, et al.
Publicado: (2018)

Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016
por: Hellmund, Peter, et al.
Publicado: (2020)

Systemic Therapy of Metastatic Melanoma: On the Road to Cure
por: Steininger, Julian, et al.
Publicado: (2021)

Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis
por: Brütting, Julia, et al.
Publicado: (2018)

Conventional and three-dimensional photography as a tool to map distribution patterns of in-transit melanoma metastases on the lower extremity
por: Müller, Kilian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_64q20hivpc8dq3df2kgn2a30vr